Most peptides sold for research use have never been given to a person under study conditions. Selank is the exception, and that makes it more interesting and more easily oversold. The trials exist. They are also small, old, and all from one country and one journal. This page covers what they found and what that is worth. It sits under the sleep goal, where anxiety and rest overlap.
What selank is
Selank is a synthetic analog of tuftsin, a short immune-active peptide, with a few extra amino acids added to make it last longer in the body. It was developed in Russia, and almost all of the research on it has been done there. Papers describe it as an anxiolytic, meaning a drug intended to reduce anxiety.
The three human trials
The earliest was published in 2008 [1]. It studied 62 patients with generalized anxiety disorder and neurasthenia, split between selank (n = 30) and the benzodiazepine medazepam (n = 32). Patients were assessed on the Hamilton, Zung and CGI scales. The authors reported that the anxiety effects of the two drugs were similar, and that selank additionally had antiasthenic and psychostimulant effects, meaning it did not flatten people the way the comparator tended to.
A 2014 paper compared selank with phenazepam, another benzodiazepine, in 60 patients with phobic-anxiety and somatoform disorders [2]. It reported a pronounced anxiety effect and a mild nootropic one, and made a claim worth noting: the anxiety effect persisted for a week after the last dose.
A 2015 paper from an overlapping group took a different design [3]. Rather than selank against a benzodiazepine, it compared phenazepam alone (n = 30) with phenazepam plus selank (n = 40), in anxiety-phobic, hypochondriac and somatoform disorders. Outcomes were measured with HDRS, CGI and Spielberger scales, tolerability with the UKU scale, and cognition with the Stroop and verbal fluency tests.
How much that is worth
Around 190 patients across three studies is not nothing, and it is not much. For comparison, the trials that support an approved anxiety drug run to thousands of participants across multiple countries.
There is also no registered trial. ClinicalTrials.gov lists no study with selank as an intervention, so no protocol, endpoint or result has been lodged in the registry that Western regulators read.
Where it stands with the FDA
Selank appears on neither FDA bulk drug substance list: not in the 503A categories, updated May 14, 2026, and not in the 503B categories, updated March 21, 2025. No pharmacy has a lawful route to compound it, whatever the Russian trials found.
For how that framework decides what a pharmacy may prepare, see what makes a peptide legal to prescribe. For a compound with the opposite evidence profile, plenty of laboratory work and no human trial at all, see KPV, and for two more in that position, BPC-157 and TB-500.